236 related articles for article (PubMed ID: 17088973)
1. In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein.
Bian H; Wilden H; Fournier P; Peeters B; Schirrmacher V
Int J Oncol; 2006 Dec; 29(6):1359-69. PubMed ID: 17088973
[TBL] [Abstract][Full Text] [Related]
2. Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein.
Bian H; Fournier P; Moormann R; Peeters B; Schirrmacher V
Int J Oncol; 2005 Feb; 26(2):431-9. PubMed ID: 15645128
[TBL] [Abstract][Full Text] [Related]
3. Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein.
Bian H; Fournier P; Peeters B; Schirrmacher V
Int J Oncol; 2005 Aug; 27(2):377-84. PubMed ID: 16010418
[TBL] [Abstract][Full Text] [Related]
4. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
5. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
[TBL] [Abstract][Full Text] [Related]
6. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus.
Vigil A; Park MS; Martinez O; Chua MA; Xiao S; Cros JF; Martínez-Sobrido L; Woo SL; García-Sastre A
Cancer Res; 2007 Sep; 67(17):8285-92. PubMed ID: 17804743
[TBL] [Abstract][Full Text] [Related]
7. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
8. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
9. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application.
Apostolidis L; Schirrmacher V; Fournier P
Int J Oncol; 2007 Nov; 31(5):1009-19. PubMed ID: 17912426
[TBL] [Abstract][Full Text] [Related]
10. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors.
Yaacov B; Eliahoo E; Lazar I; Ben-Shlomo M; Greenbaum I; Panet A; Zakay-Rones Z
Cancer Gene Ther; 2008 Dec; 15(12):795-807. PubMed ID: 18535620
[TBL] [Abstract][Full Text] [Related]
11. Apoptin enhances the oncolytic properties of Newcastle disease virus.
Wu Y; Zhang X; Wang X; Wang L; Hu S; Liu X; Meng S
Intervirology; 2012; 55(4):276-86. PubMed ID: 21865658
[TBL] [Abstract][Full Text] [Related]
12. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy.
Kanai R; Eguchi K; Takahashi M; Goldman S; Okano H; Kawase T; Yazaki T
J Gene Med; 2006 Nov; 8(11):1329-40. PubMed ID: 16955534
[TBL] [Abstract][Full Text] [Related]
13. Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus.
Bian H; Fournier P; Moormann R; Peeters B; Schirrmacher V
Cancer Gene Ther; 2005 Mar; 12(3):295-303. PubMed ID: 15605075
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy.
Janke M; Peeters B; de Leeuw O; Moorman R; Arnold A; Fournier P; Schirrmacher V
Gene Ther; 2007 Dec; 14(23):1639-49. PubMed ID: 17914407
[TBL] [Abstract][Full Text] [Related]
15. Targeting gene-virotherapy of cancer.
Liu XY; Gu JF
Cell Res; 2006 Jan; 16(1):25-30. PubMed ID: 16467873
[TBL] [Abstract][Full Text] [Related]
16. [Progress in using Newcastle disease virus for tumor therapy: a review].
Wu Y; Hao J; Li D
Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic adenoviruses - selective retargeting to tumor cells.
Mathis JM; Stoff-Khalili MA; Curiel DT
Oncogene; 2005 Nov; 24(52):7775-91. PubMed ID: 16299537
[TBL] [Abstract][Full Text] [Related]
18. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
[TBL] [Abstract][Full Text] [Related]
19. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
20. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
